PERSISTENCE OF FALSE POSITIVE SERUM LEVELS OF (1-3)-ß-D-GLUCAN AFTER INFUSION OF INTRAVENOUS IMMUNOGLOBULINS

Author(s):  
Volker Strenger
2018 ◽  
Vol 76 (2) ◽  
pp. 206-210 ◽  
Author(s):  
M. Egger ◽  
F. Prüller ◽  
R. Raggam ◽  
M.K. Divjak ◽  
S. Kurath-Koller ◽  
...  

2003 ◽  
Vol 84 (1) ◽  
pp. 48-52
Author(s):  
Detlef Zillikens ◽  
Susanne Herzog ◽  
Enno Schmidt ◽  
Matthias Goebeler ◽  
Bröcker Eva-B.

1989 ◽  
Vol 4 (2) ◽  
pp. 87-94 ◽  
Author(s):  
J. Morote Robles ◽  
A. Ruibal Morell ◽  
J.A. De Torres Mateos ◽  
A. Soler Roselló

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.


1993 ◽  
Vol 39 (6) ◽  
pp. 1355-1356 ◽  
Author(s):  
F H Wians ◽  
J T Norton ◽  
S R Wirebaugh

2010 ◽  
Vol 42 (6-7) ◽  
pp. 461-468 ◽  
Author(s):  
Viboon Boonsarngsuk ◽  
Anuchit Niyompattama ◽  
Chalermporn Teosirimongkol ◽  
Kanchana Sriwanichrak

2020 ◽  
Vol 58 (6) ◽  
Author(s):  
Qiang Wang ◽  
Qin Du ◽  
Bin Guo ◽  
Daiyong Mu ◽  
Xiaolan Lu ◽  
...  

ABSTRACT We set out to investigate the interference factors that led to false-positive novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM detection results using gold immunochromatography assay (GICA) and enzyme-linked immunosorbent assay (ELISA) and the corresponding solutions. GICA and ELISA were used to detect SARS-CoV-2 IgM in 86 serum samples, including 5 influenza A virus (Flu A) IgM-positive sera, 5 influenza B virus (Flu B) IgM-positive sera, 5 Mycoplasma pneumoniae IgM-positive sera, 5 Legionella pneumophila IgM-positive sera, 6 sera of HIV infection patients, 36 rheumatoid factor IgM (RF-IgM)-positive sera, 5 sera from hypertensive patients, 5 sera from diabetes mellitus patients, and 14 sera from novel coronavirus infection disease 19 (COVID-19) patients. The interference factors causing false-positive reactivity with the two methods were analyzed, and the urea dissociation test was employed to dissociate the SARS-CoV-2 IgM-positive serum using the best dissociation concentration. The two methods detected positive SARS-CoV-2 IgM in 22 mid-to-high-level-RF-IgM-positive sera and 14 sera from COVID-19 patients; the other 50 sera were negative. At a urea dissociation concentration of 6 mol/liter, SARS-CoV-2 IgM results were positive in 1 mid-to-high-level-RF-IgM-positive serum and in 14 COVID-19 patient sera detected using GICA. At a urea dissociation concentration of 4 mol/liter and with affinity index (AI) levels lower than 0.371 set to negative, SARS-CoV-2 IgM results were positive in 3 mid-to-high-level-RF-IgM-positive sera and in 14 COVID-19 patient sera detected using ELISA. The presence of RF-IgM at mid-to-high levels could lead to false-positive reactivity of SARS-CoV-2 IgM detected using GICA and ELISA, and urea dissociation tests would be helpful in reducing SARS-CoV-2 IgM false-positive results.


1983 ◽  
Vol 5 (3) ◽  
pp. 245-250 ◽  
Author(s):  
Charles E. Brady ◽  
Randle C. Johnson ◽  
Josie R. Williams ◽  
Kevin Boran

Sign in / Sign up

Export Citation Format

Share Document